Emerging Pharmaceutical Mass Torts for Plaintiff Attorneys
Explore emerging prescription drug litigation, pharmaceutical case developments, and evolving mass tort opportunities at Mass Torts Made Perfect.
- Emerging pharmaceutical litigation trends
- MDL and regulatory developments
- Case evaluation and litigation strategy
- Referral and co-counsel networking
Understanding Today's Pharmaceutical Mass Tort Landscape
Pharmaceutical mass tort litigation continues to evolve as new safety concerns emerge, scientific research advances, and regulatory actions shape potential claims. Staying informed on developing drug litigation helps plaintiff attorneys identify new case opportunities, strengthen case strategies, and better serve their clients.
Pharmaceutical Litigation Topics Covered at MTMP
MTMP programming highlights emerging pharmaceutical litigation that may present opportunities for plaintiff firms. Educational sessions are designed to help attorneys stay informed as the legal landscape continues to evolve, with discussions covering topics such as:
GLP-1 Receptor Agonist Litigation
GLP-1 receptor agonist litigation continues to evolve as lawsuits involving Ozempic®, Wegovy®, Mounjaro®, Zepbound®, and similar medications move through coordinated federal proceedings. Current claims generally focus on alleged failures to warn about serious gastrointestinal injuries, including gastroparesis, ileus, and intestinal obstruction, while separate litigation is developing around alleged vision loss injuries, including non-arteritic anterior ischemic optic neuropathy (NAION).
Hair Relaxer Litigation
The hair relaxer litigation remains an important area of mass tort litigation as claims involving chemical hair straightening products continue through coordinated federal proceedings. Plaintiffs allege that long-term use of certain products is associated with hormone-related cancers, including uterine, ovarian, and endometrial cancer.
Olympus Scopes Litigation
The Olympus scope litigation involves allegations that certain reusable endoscopes, duodenoscopes, bronchoscopes, and related medical devices may expose patients to serious infections or injuries when devices are difficult to properly clean, disinfect, or reprocess between procedures. FDA safety communications and import alerts involving certain Olympus devices have kept attention on device design, reprocessing protocols, infection risk, hospital records, and causation evidence. x proof issues tied to procedure timelines and post-procedure complications.
Dupixent Litigation
The Dupixent litigation is an emerging pharmaceutical mass tort involving allegations that dupilumab may be associated with cutaneous T-cell lymphoma (CTCL) and that the medication may mask or delay diagnosis in certain patients. As coordinated federal litigation moves forward, plaintiff attorneys should continue following developments in medical research, expert testimony, case criteria, and regulatory issues that may shape the future of these claims.
Why Plaintiff Attorneys Attend MTMP
Mass Torts Made Perfect brings together plaintiff attorneys, litigation leaders, and industry experts to discuss emerging mass tort developments, evolving case strategies, and opportunities across the pharmaceutical litigation landscape.
Whether you’re following GLP-1 litigation, Hair Relaxer, Johnson & Johnson Talc, Olympus Scope, Dupixent, or the next wave of emerging pharmaceutical claims, MTMP provides practical education, timely litigation updates, and valuable networking opportunities with attorneys actively handling these cases.